Free Trial
NASDAQ:BNR

Burning Rock Biotech Q4 2024 Earnings Report

Burning Rock Biotech logo
$2.84 -0.10 (-3.40%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$2.86 +0.02 (+0.53%)
As of 04/25/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Burning Rock Biotech EPS Results

Actual EPS
-$1.08
Consensus EPS
-$1.40
Beat/Miss
Beat by +$0.32
One Year Ago EPS
N/A

Burning Rock Biotech Revenue Results

Actual Revenue
$17.27 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Burning Rock Biotech Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 25, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Burning Rock Biotech's Q1 2025 earnings is scheduled for Monday, May 26, 2025, with a conference call scheduled on Wednesday, May 28, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Burning Rock Biotech Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Burning Rock Biotech’s Strategic Growth and Financial Results
See More Burning Rock Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Burning Rock Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Burning Rock Biotech and other key companies, straight to your email.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ:BNR) primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

View Burning Rock Biotech Profile

More Earnings Resources from MarketBeat